Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia

Leukemia

Volumn 28, Issue 2, 2014, Pages 440-443

  Recher C ^a   Bene M C ^b   Lioure, B ^c   Pigneux, A ^d   Vey, N ^e   Delaunay, J ^b   Luquet, I ^a   Hunault, M ^f   Guyotat, D ^g   Bouscary, D ^h   Fegueux, N ⁱ   Jourdan, E ^j   Lissandre, S ^k   Escoffre Barbe, M ^l   Bonmati, C ^m   Randriamalala, E ⁿ   Guieze R ^o   Ojeda Uribe, M ^p   Dreyfus, F ^h   Harousseau, J L ^q   Cahn, J Y ^r   Ifrah, N ^f   Guardiola, P ^f   more..

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j Centre Hospitalier Universitaire de Ný mes   (France)

^k UNIVERSITY HOSPITAL OF TOURS   (France)

^l RENNES UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF NANCY   (France)

ⁿ POITIERS UNIVERSITY HOSPITAL   (France)

^o UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^p Hôpitaux Universitaires de Strasbourg   (France)

^q CENTRE RENÉ GAUDUCHEAU   (France)

^r GRENOBLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DAUNORUBICIN; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893797218     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.290     Document Type: Letter

References (15)

1. Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program 2009 396-405.
2. Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011; 364: 1027-1036.
3. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249-1259.
4. Chevallier P, Fornecker L, Lioure B, Bene MC, Pigneux A, Recher C et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia 2010; 24: 1380-1385.
5. Lioure B, Bene MC, Pigneux A, Huynh A, Chevallier P, Fegueux N et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood 2012; 119: 2943-2948.
6. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl JMed 2009; 361: 1235-1248.
7. AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998; 103: 100-109.
8. Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013; 161: 192-203.
9. Wang J, Yang YG, Zhou M, Xu JY, Zhang QG, Zhou RF et al. Meta-analysis of randomised clinical trials comparing idarubicin\+cytarabine with daunorubicin\+cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. PLoS One 2013; 8: e60699.
10. Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol 2012; 31: 321-327.
11. Wiernik PH, Banks PL, Case Jr DC, Arlin ZA, Periman PO, Todd MB et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313-319.
12. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27: 5397-5403.
13. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 2011; 117: 2358-2365.
14. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
15. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.